AIDS Therapies

Phase I SBIR Grant Awarded to Develop HIV Treatments

Published in AIDS Weekly, January 8th, 2001

PTC Therapeutics, Plainfield, New Jersey, announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health (NIH).

Funding from this grant will be used to advance PTC's RNA-based approach for developing novel HIV drugs that target the mechanism the virus uses to replicate. The company's unique approach is based on interfering with an essential protein production process - called "programmed ribosomal frameshifting" - required by the virus for its survival.

The usual process of producing proteins is highly accurate and ensures that individual mRNAs will almost always lead to very...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry